Contact
searchSearch
HMP Global

Rheumatology

Featured Article

News
Machine Learning Models Identify Patients With Rheumatoid Arthritis At Risk for Treatment Nonadherence
03/20/2026
Lisa Kuhns, PhD, MD
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help...
03/20/2026
First Report Managed Care
News
Payer Coverage Decisions Shape Access to Myasthenia Gravis Therapies
03/12/2026
Grace Taylor, MS, MA
Payer coverage design, beyond drug cost alone, is shaping patient access to emerging myasthenia gravis therapies and driving the need for more flexible, individualized treatment models.
Payer coverage design, beyond drug cost alone, is shaping patient access to emerging myasthenia gravis therapies and driving the need for more flexible, individualized treatment models.
Payer coverage design, beyond...
03/12/2026
First Report Managed Care
News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
News
Study Highlights Motivators and Barriers to Clinical Trial Enrollment in Rheumatoid Arthritis
05/07/2025
Grace Taylor, MS, MA
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what...
05/07/2025
First Report Managed Care
News
Patients With Rheumatoid Arthritis Experience Substantial Economic and Quality-of-Life Burden
04/08/2025
Grace Taylor, MS, MA
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data,...
04/08/2025
First Report Managed Care
News
Adverse Events Common With Glucocorticoids for Polymyalgia Rheumatica
04/17/2024
Jolynn Tumolo
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid...
04/17/2024
First Report Managed Care
News
Identifying Large-Vessel Vasculitis in Polymyalgia Rheumatica: Key Clinical and Laboratory Red Flags
04/05/2024
Lisa Kuhns, PhD, MD
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for...
04/05/2024
First Report Managed Care
News
Potential for Target-To-Treat Strategies for Polymyalgia Rheumatica and Giant Cell Arthritis
03/28/2024

Emry Lloyd

Emry Lloyd
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat...
03/28/2024
First Report Managed Care
News
Task Force Publishes Target-To-Treat Guidance for GCA and PMR
03/12/2024
Jolynn Tumolo
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force...
03/12/2024
First Report Managed Care
News
Therapy Reduces Disease Activity in Patients With Polymyalgia Rheumatica
02/15/2023
Hannah Musick
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced...
02/15/2023
First Report Managed Care
News
Adalimumab vs Etanercept for Rheumatoid Arthritis: Comparing Adverse Reactions, Drug Survival
02/03/2023
Jolynn Tumolo
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the...
02/03/2023
First Report Managed Care

Newsfeed

News
Machine Learning Models Identify Patients With Rheumatoid Arthritis At Risk for Treatment Nonadherence
03/20/2026
Lisa Kuhns, PhD, MD
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help...
03/20/2026
First Report Managed Care
News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
News
Study Highlights Motivators and Barriers to Clinical Trial Enrollment in Rheumatoid Arthritis
05/07/2025
Grace Taylor, MS, MA
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what...
05/07/2025
First Report Managed Care
News
Patients With Rheumatoid Arthritis Experience Substantial Economic and Quality-of-Life Burden
04/08/2025
Grace Taylor, MS, MA
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data,...
04/08/2025
First Report Managed Care
News
Adverse Events Common With Glucocorticoids for Polymyalgia Rheumatica
04/17/2024
Jolynn Tumolo
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid...
04/17/2024
First Report Managed Care
News
Identifying Large-Vessel Vasculitis in Polymyalgia Rheumatica: Key Clinical and Laboratory Red Flags
04/05/2024
Lisa Kuhns, PhD, MD
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for...
04/05/2024
First Report Managed Care
News
Potential for Target-To-Treat Strategies for Polymyalgia Rheumatica and Giant Cell Arthritis
03/28/2024

Emry Lloyd

Emry Lloyd
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat...
03/28/2024
First Report Managed Care
News
Task Force Publishes Target-To-Treat Guidance for GCA and PMR
03/12/2024
Jolynn Tumolo
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force...
03/12/2024
First Report Managed Care
News
Therapy Reduces Disease Activity in Patients With Polymyalgia Rheumatica
02/15/2023
Hannah Musick
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced...
02/15/2023
First Report Managed Care
News
Adalimumab vs Etanercept for Rheumatoid Arthritis: Comparing Adverse Reactions, Drug Survival
02/03/2023
Jolynn Tumolo
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the...
02/03/2023
First Report Managed Care
News
Medicaid Coverage Remains Suboptimal After Medicare Enrollment
08/03/2026
Rebecca Amrick
A study found that waiving the Medicare Savings Program (MSP) asset test could help newly enrolled Medicare beneficiaries retain Medicaid coverage, but variations in state-level coverage and suboptimal rates of enrollment raise concerns about...
A study found that waiving the Medicare Savings Program (MSP) asset test could help newly enrolled Medicare beneficiaries retain Medicaid coverage, but variations in state-level coverage and suboptimal rates of enrollment raise concerns about...
A study found that waiving the...
08/03/2026
First Report Managed Care
Behind the Bill
Court Challenge Tests CMS' New Medicaid Work Requirement Rule
07/31/2026
Hannah Musick
A federal court has allowed CMS' new Medicaid work requirement rule to move forward while a multistate legal challenge continues, setting the stage for a broader debate over how the landmark eligibility changes will be implemented nationwide.
A federal court has allowed CMS' new Medicaid work requirement rule to move forward while a multistate legal challenge continues, setting the stage for a broader debate over how the landmark eligibility changes will be implemented nationwide.
A federal court has allowed CMS'...
07/31/2026
First Report Managed Care
News
GLP-1 RAs Have Higher Utilization Among Patients With Obesity Than Bariatric Surgery
07/28/2026
Rebecca Amrick
A study found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the more common treatment option for obesity among adolescents and young adults compared to bariatric surgery.
A study found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the more common treatment option for obesity among adolescents and young adults compared to bariatric surgery.
A study found that glucagon-like...
07/28/2026
First Report Managed Care
News
Kidney Transplant Referrals Show Significant Attrition Before Waitlisting
07/28/2026
Grace Taylor, MS, MA
A large US electronic health record analysis found that only 1 in 10 patients referred for kidney transplantation ultimately received a transplant, highlighting substantial attrition before waitlisting and identifying key patient- and...
A large US electronic health record analysis found that only 1 in 10 patients referred for kidney transplantation ultimately received a transplant, highlighting substantial attrition before waitlisting and identifying key patient- and...
A large US electronic health...
07/28/2026
First Report Managed Care
News
Insurance Coverage Impacts Episode of Care for Spinal Fusions
07/27/2026
Rebecca Amrick
A study found that among patients who underwent lumbar fusions, those covered by Medicare Advantage had longer lengths of stay and higher rates of home discharges than those covered by Medicare Fee-For-Service, illustrating gaps in episode of...
A study found that among patients who underwent lumbar fusions, those covered by Medicare Advantage had longer lengths of stay and higher rates of home discharges than those covered by Medicare Fee-For-Service, illustrating gaps in episode of...
A study found that among...
07/27/2026
First Report Managed Care
News
US Study Identifies Factors Linked to Low Metabolic Bariatric Surgery Uptake
07/24/2026
Grace Taylor, MS, MA
A large US cohort study found that only 3% of adults newly diagnosed with obesity underwent metabolic bariatric surgery within one year, with provider type, body mass index, sex, and other clinical factors strongly influencing access to...
A large US cohort study found that only 3% of adults newly diagnosed with obesity underwent metabolic bariatric surgery within one year, with provider type, body mass index, sex, and other clinical factors strongly influencing access to...
A large US cohort study found...
07/24/2026
First Report Managed Care
Behind the Bill
Federal Court Pauses Key ACA Marketplace Rule Changes
07/23/2026
Hannah Musick
A federal court has temporarily blocked several key provisions of Centers for Medicare & Medicaid Services' (CMS') 2027 Affordable Care Act (ACA) Marketplace rule, setting up a high-stakes legal battle over federal authority, Marketplace...
A federal court has temporarily blocked several key provisions of Centers for Medicare & Medicaid Services' (CMS') 2027 Affordable Care Act (ACA) Marketplace rule, setting up a high-stakes legal battle over federal authority, Marketplace...
A federal court has temporarily...
07/23/2026
First Report Managed Care
News
CMS Proposes New Medicaid Provider Tax Thresholds Under WFTC Legislation
07/23/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has proposed sweeping changes to Medicaid provider tax regulations that would establish new indirect hold harmless thresholds, expand reporting requirements, and reshape state health...
The Centers for Medicare & Medicaid Services (CMS) has proposed sweeping changes to Medicaid provider tax regulations that would establish new indirect hold harmless thresholds, expand reporting requirements, and reshape state health...
The Centers for Medicare &...
07/23/2026
First Report Managed Care
News
Fabhalta (Iptacopan) Receives FDA Approval to Slow Disease Progression in Patients With IgAN
07/22/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) recently approved Fabhalta (iptacopan) to slow kidney function decline in patients with immunoglobulin A nephropathy (IgAN).
The US Food and Drug Administration (FDA) recently approved Fabhalta (iptacopan) to slow kidney function decline in patients with immunoglobulin A nephropathy (IgAN).
The US Food and Drug...
07/22/2026
First Report Managed Care
News
Obesity Subphenotype With Low GLP-1 Levels Shows Greater Weight Loss With Tirzepatide
07/21/2026
Hannah Musick
Researchers identified an obesity subphenotype characterized by rapid gastric emptying and low endogenous GLP-1 production that achieved nearly twice the weight loss with tirzepatide as other obesity phenotypes, highlighting the potential for...
Researchers identified an obesity subphenotype characterized by rapid gastric emptying and low endogenous GLP-1 production that achieved nearly twice the weight loss with tirzepatide as other obesity phenotypes, highlighting the potential for...
Researchers identified an...
07/21/2026
First Report Managed Care

Insights

Interview
Lower Costs, Improved Outcomes for Patients Achieving Early RA Remission
07/23/2019
Peter M ten Klooster, PhD, assistant professor at the University of Twente in Enschede in the Netherlands, discusses why achieving early remission for patients with rheumatoid arthritis is important to payers and how it can result in...
Peter M ten Klooster, PhD, assistant professor at the University of Twente in Enschede in the Netherlands, discusses why achieving early remission for patients with rheumatoid arthritis is important to payers and how it can result in...
Peter M ten Klooster, PhD,...
07/23/2019
First Report Managed Care
Interview
Impact of Artificial Intelligence on Patient Outcomes, Cost of Care in RA
06/20/2019
Beau Norgeot, MS, of Bakar Computational Health Sciences Institute at the University of California, explains how artificial intelligence (AI) impacts the cost of care for patients with complex diseases, including rheumatoid arthritis, and...
Beau Norgeot, MS, of Bakar Computational Health Sciences Institute at the University of California, explains how artificial intelligence (AI) impacts the cost of care for patients with complex diseases, including rheumatoid arthritis, and...
Beau Norgeot, MS, of Bakar...
06/20/2019
First Report Managed Care
Interview
High Out-of-Pocket Costs Increase Medication Nonadherence Among Patients With RA
06/06/2019
Julie Gould
Parvaneh Heidari, PhD student at Monash University, explains why it is recommended that health policy makers globally identify an appropriate out-of-pocket amount to ensure costs do not affect medication adherence among patients with...
Parvaneh Heidari, PhD student at Monash University, explains why it is recommended that health policy makers globally identify an appropriate out-of-pocket amount to ensure costs do not affect medication adherence among patients with...
Parvaneh Heidari, PhD student at...
06/06/2019
First Report Managed Care
Interview
Techniques Used to Lessen Opioid Use, Address Rheumatologic Pain
05/09/2019
Nirav N Shah, MD, attending anesthesiologist and interventional pain management specialist at Northshore University Health System, explains how neuromodulation can help lessen pain caused by rheumatologic conditions as well as reduce opioid...
Nirav N Shah, MD, attending anesthesiologist and interventional pain management specialist at Northshore University Health System, explains how neuromodulation can help lessen pain caused by rheumatologic conditions as well as reduce opioid...
Nirav N Shah, MD, attending...
05/09/2019
First Report Managed Care
Interview
Why Higher Levels of Physical Activity Are Important in Preventing Chronic Diseases
04/11/2019
Jeffrey Sparks, MD, rheumatologist and population scientist, discusses the importance of high levels of physical activity and explains why he suspects physical activity has beneficial effects on the immune system and also lowers systemic...
Jeffrey Sparks, MD, rheumatologist and population scientist, discusses the importance of high levels of physical activity and explains why he suspects physical activity has beneficial effects on the immune system and also lowers systemic...
Jeffrey Sparks, MD,...
04/11/2019
First Report Managed Care
Interview
Assessing the Safety of a Treatment With A Label Warning for Patients With RA, COPD
04/08/2019
Samy Suissa, PhD, professor of Epidemiology, Biostatistics and Medicine at McGill University in Montreal, discusses a label warning on a rheumatoid arthritis (RA) drug for patients with RA and COPD and he explains that the choice of biologic...
Samy Suissa, PhD, professor of Epidemiology, Biostatistics and Medicine at McGill University in Montreal, discusses a label warning on a rheumatoid arthritis (RA) drug for patients with RA and COPD and he explains that the choice of biologic...
Samy Suissa, PhD, professor of...
04/08/2019
First Report Managed Care
Interview
Exploring the Cost Benefits of Cloud-Enabled Testing for RA Diagnosis
03/14/2019
Kata Bognar, PhD, research economist at Precision Health Economics, discusses how rapid, cloud-enabled, onsite lab testing for RA diagnosis is valuable to payers and can potentially lower the number of visits per patient.
Kata Bognar, PhD, research economist at Precision Health Economics, discusses how rapid, cloud-enabled, onsite lab testing for RA diagnosis is valuable to payers and can potentially lower the number of visits per patient.
Kata Bognar, PhD, research...
03/14/2019
First Report Managed Care
Interview
Improving Access to Care, Outcomes Through Telemedicine for Patients With RA
03/06/2019
Wendy Marder, MD, associate professor and clinical service chief of the division of rheumatology at Michigan Medicine in Ann Arbor, Michigan, discusses telemedicine in a rheumatology setting and explains how telemedicine will impact...
Wendy Marder, MD, associate professor and clinical service chief of the division of rheumatology at Michigan Medicine in Ann Arbor, Michigan, discusses telemedicine in a rheumatology setting and explains how telemedicine will impact...
Wendy Marder, MD, associate...
03/06/2019
First Report Managed Care
Ben Derman
Interview
Navigating the Next Phase of Multiple Myeloma Treatment: Balancing Innovation, Access, and Evidence
07/23/2026
Ben Derman, MD
In this interview, a guest expert shares insights discussed at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting about the updated ASCO Living Guideline for multiple myeloma, including broader use of quadruplet regimens,...
In this interview, a guest expert shares insights discussed at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting about the updated ASCO Living Guideline for multiple myeloma, including broader use of quadruplet regimens,...
In this interview, a guest...
07/23/2026
First Report Managed Care
PIPELINE PROJECTIONS
The Evolving Alzheimer Disease Treatment Landscape: Anti-Amyloid Therapies and Beyond
07/21/2026
Roy Moore
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving...
07/21/2026
First Report Managed Care
LC
Interview
The Next Phase of Value-Based Care: From Evidence to Implementation
07/20/2026
Lynn Carroll
In this interview, a guest expert discusses how health plans are evaluating innovative therapies through the lens of value-based care and explains why real-world evidence, interoperable data, and scalable contract infrastructure are essential...
In this interview, a guest expert discusses how health plans are evaluating innovative therapies through the lens of value-based care and explains why real-world evidence, interoperable data, and scalable contract infrastructure are essential...
In this interview, a guest...
07/20/2026
First Report Managed Care
BI FRMC KOL video
Videos
Beyond FVC: What FIBRONEER-ILD Means for Outcomes, Patients, and Access in PPF
07/01/2026
Toby Maher, MD, PhD
In this expert commentary, Dr Toby Maher discusses the evolving treatment landscape in progressive pulmonary fibrosis (PPF) and the potential implications of the longer-term FIBRONEER-ILD trial findings. He explores how nerandomilast may...
In this expert commentary, Dr Toby Maher discusses the evolving treatment landscape in progressive pulmonary fibrosis (PPF) and the potential implications of the longer-term FIBRONEER-ILD trial findings. He explores how nerandomilast may...
In this expert commentary, Dr...
07/01/2026
First Report Managed Care
MANAGED CARE Q&A
From Innovation to Access: Overcoming Reimbursement Challenges for Cell and Gene Therapies
06/25/2026
Joe DePinto
This interview explores the structural, operational, and reimbursement challenges limiting access to cell and gene therapies, highlighting the importance of stakeholder collaboration, innovative payment models, real-world evidence, and...
This interview explores the structural, operational, and reimbursement challenges limiting access to cell and gene therapies, highlighting the importance of stakeholder collaboration, innovative payment models, real-world evidence, and...
This interview explores the...
06/25/2026
First Report Managed Care
BI FRMC Clinical Outcomes That Matter
Podcasts
Clinical Outcomes That Matter: FIBRONEER-ILD and the Future of PPF Management
06/25/2026
Toby Maher, MD, PhD
In this expert commentary, Dr Toby Maher discusses the evolving treatment landscape in progressive pulmonary fibrosis (PPF) and the implications of the extended follow-up findings from the FIBRONEER-ILD trial. He explores the potential role...
In this expert commentary, Dr Toby Maher discusses the evolving treatment landscape in progressive pulmonary fibrosis (PPF) and the implications of the extended follow-up findings from the FIBRONEER-ILD trial. He explores the potential role...
In this expert commentary, Dr...
06/25/2026
First Report Managed Care
Debra Patt
Interview
How Electronic Patient-Reported Outcomes Are Transforming Symptom Management and Value-Based Cancer Care
06/19/2026
Debra A. Patt, MD, PhD, MBA
In this interview, Deborah Patt, MD, PhD, MBA, discusses data presented at the 2026 American Society of Clinical Oncology Annual Meeting showing how electronic patient-reported outcomes and remote therapeutic monitoring can improve symptom...
In this interview, Deborah Patt, MD, PhD, MBA, discusses data presented at the 2026 American Society of Clinical Oncology Annual Meeting showing how electronic patient-reported outcomes and remote therapeutic monitoring can improve symptom...
In this interview, Deborah Patt,...
06/19/2026
First Report Managed Care
Jill Hellmann
Interview
Rethinking Cancer Attribution in Value-Based Oncology Care
06/03/2026
Jill Hellmann, MSN, RN
In this interview, a guest expert discusses research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on how the growing use of oral oncolytics and the increasing prevalence of concurrent cancers may expose...
In this interview, a guest expert discusses research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on how the growing use of oral oncolytics and the increasing prevalence of concurrent cancers may expose...
In this interview, a guest...
06/03/2026
First Report Managed Care
Nephrology, kidney disease
Managed Care Insights
The Evolving Nephrology Landscape: Treatment, Innovation, and Policy: Part 3
05/29/2026
Suzanne Watnick, MD
Suzanne Watnick, MD, explains why earlier chronic kidney disease detection, broader access to proven therapies, and reimbursement policies that support innovation are critical to improving kidney care outcomes and reducing progression to...
Suzanne Watnick, MD, explains why earlier chronic kidney disease detection, broader access to proven therapies, and reimbursement policies that support innovation are critical to improving kidney care outcomes and reducing progression to...
Suzanne Watnick, MD, explains...
05/29/2026
First Report Managed Care
Nephrology, kidney disease
Managed Care Insights
The Evolving Nephrology Landscape: Treatment, Innovation, and Policy: Part 2
05/29/2026
Suzanne Watnick, MD
Dr Suzanne Watnick examines how greater investment, equitable policies, and stakeholder collaboration will be essential to ensuring that emerging kidney therapies improve outcomes without widening existing disparities in care.
Dr Suzanne Watnick examines how greater investment, equitable policies, and stakeholder collaboration will be essential to ensuring that emerging kidney therapies improve outcomes without widening existing disparities in care.
Dr Suzanne Watnick examines how...
05/29/2026
First Report Managed Care
First Report Managed Care

Current Issue

June 2026
Volume 23
Issue 2
Current Issue
Issue Archive

Recent Stories

News
Machine Learning Models Identify Patients With Rheumatoid Arthritis At Risk for Treatment Nonadherence
03/20/2026
Lisa Kuhns, PhD, MD
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help...
03/20/2026
First Report Managed Care
News
Payer Coverage Decisions Shape Access to Myasthenia Gravis Therapies
03/12/2026
Grace Taylor, MS, MA
Payer coverage design, beyond drug cost alone, is shaping patient access to emerging myasthenia gravis therapies and driving the need for more flexible, individualized treatment models.
Payer coverage design, beyond drug cost alone, is shaping patient access to emerging myasthenia gravis therapies and driving the need for more flexible, individualized treatment models.
Payer coverage design, beyond...
03/12/2026
First Report Managed Care
News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
News
Study Highlights Motivators and Barriers to Clinical Trial Enrollment in Rheumatoid Arthritis
05/07/2025
Grace Taylor, MS, MA
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what...
05/07/2025
First Report Managed Care
News
Patients With Rheumatoid Arthritis Experience Substantial Economic and Quality-of-Life Burden
04/08/2025
Grace Taylor, MS, MA
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data,...
04/08/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use